NEWTOWN, Pa., Sept. 09, 2022 (GLOBE NEWSWIRE) — The law firm of Edelson Lechtzin LLP is investigating securities fraud lawsuits on behalf of all purchasers of Enochian Biosciences Inc. (“Enochian” or the “Company”) NOV Common Shares between February 16, 2018 and June 27, 2022 inclusive (the “Class Period”).

Investors who purchased Enochian Biosciences common stock during the Class Period may apply in the United States District Court for the Central District of California to appoint them lead plaintiffs 09/26/2022. A lead plaintiff is a representative party acting on behalf of other group members in conducting the litigation. Investors wishing to discuss the lead plaintiff selection process should contact Edelson Lechtzin LLP toll free at 1-844-696-7492 or email at [email protected].

Background on the class action lawsuit against Enochian Biosciences securities

Enochian is a preclinical-stage biotechnology company purportedly discovering and developing pharmaceutical and biological products for the treatment of human immunodeficiency virus (“HIV”), hepatitis B virus (“HBV”), influenza and coronavirus infections, and cancer .

The lawsuit alleges that the defendants made false and/or misleading statements regarding the Company’s financial performance and future prospects throughout the class period. In particular, it is alleged that: Enochian co-founder Gumrukcu was involved in a variety of scams; Gumrukcu was not a licensed physician and had no degrees beyond high school. Accordingly, the scientific and technological basis of Enochian’s product pipeline allegedly invented by Gumrukcu was dubious at best, and Defendants grossly exaggerated the commercial prospects for the Company’s product pipeline. Enochian management was aware of Gumrukcu’s criminal history, which included fraud, which is why Enochian’s reliance on Gumrukcu – and the company’s consulting and licensing agreements with G-Tech and SRI – led the company…